Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
Freising, July 26, 2017 /XL-protein/ -- Jazz Pharmaceuticals…
AdAlta and XL-protein announce collaboration to develop a long acting version of its lead fibrosis drug candidate AD-114 using PASylation® Technology
Melbourne, Australia and FREISING, Germany, 7 November 2016:…
Akari Therapeutics Plc and XL-protein GmbH Sign License Agreement to Develop a Long Acting Version of Coversin Using PASylation® Technology
NEW YORK, LONDON, and FREISING, Germany, April 14, 2016 - Akari…